CIK 0000921114 · Non-accelerated filer<br>Smaller reporting company
Armata Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ARMP
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- WA
- Entity type
- operating
- EIN
- 911549568
- Phone
- 310-665-2928
- Business address
- 5005 MCCONNELL AVE, LOS ANGELES, CA, 90066
- Former names
- AmpliPhi Biosciences Corp, TARGETED GENETICS CORP /WA/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-10 | Birx Deborah Chief Executive Officer | Shares withheld for taxes | −14,041 | $4.26 | $60K | 198,417 |
| 2026-04-24 | Gilmer Daniel B. Director | Grant or award · Stock Options (Right to Buy) | +51,280 | 51,280 | ||
| 2026-03-14 | Kyme Pierre Chief Business Officer | Shares withheld for taxes | −1,030 | $10.54 | $11K | 9,461 |
| 2026-03-14 | Birx Deborah Chief Executive Officer | Shares withheld for taxes | −4,919 | $10.54 | $52K | 212,458 |
| 2026-03-09 | Kramer Robin Director | Grant or award · Stock Options (Right to Buy) | +25,640 | 25,640 | ||
| 2026-03-09 | Kyme Pierre Chief Business Officer | Grant or award · Stock Options (Right to Buy) | +183,142 | 183,142 | ||
| 2026-03-09 | House David Duane SVP, Finance, and PFO | Grant or award · Stock Options (Right to Buy) | +109,885 | 109,885 | ||
| 2026-03-09 | PATTI JOSEPH M Director | Grant or award · Stock Options (Right to Buy) | +25,640 | 25,640 | ||
| 2026-03-09 | Peterson Todd C. Director | Grant or award · Stock Options (Right to Buy) | +25,640 | 25,640 | ||
| 2026-03-09 | Odysseas Kostas D Director | Grant or award · Stock Options (Right to Buy) | +25,640 | 25,640 | ||
| 2026-03-09 | Birx Deborah Chief Executive Officer | Grant or award · Stock Options (Right to Buy) | +421,226 | 421,226 | ||
| 2026-03-09 | Schlesinger Sarah J. Director | Grant or award · Stock Options (Right to Buy) | +25,640 | 25,640 | ||
| 2026-03-09 | Haimovitz Jules Director | Grant or award · Stock Options (Right to Buy) | +25,640 | 25,640 | ||
| 2025-07-10 | Birx Deborah Chief Executive Officer | Shares withheld for taxes | −13,637 | $2.27 | $31K | 217,377 |
| 2025-03-14 | Birx Deborah Chief Executive Officer | Shares withheld for taxes | −6,061 | $1.95 | $12K | 231,014 |
| 2025-03-14 | Kyme Pierre Chief Business Officer | Shares withheld for taxes | −1,027 | $1.95 | $2K | 10,491 |
| 2025-02-05 | Odysseas Kostas D Director | Grant or award · Stock Options (Right to Buy) | +54,343 | 54,343 | ||
| 2025-02-05 | Schlesinger Sarah J. Director | Grant or award · Stock Options (Right to Buy) | +54,343 | 54,343 | ||
| 2025-02-05 | Peterson Todd C. Director | Grant or award · Stock Options (Right to Buy) | +54,343 | 54,343 | ||
| 2025-02-05 | PATTI JOSEPH M Director | Grant or award · Stock Options (Right to Buy) | +54,343 | 54,343 |
Page 1 of 7 · 122 trades